Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

Jessica L. Bowser, … , Kenneth Dunner Jr., Russell R. Broaddus


Ecto-5’-nucleotidase (CD73) is central to the generation of extracellular adenosine. Previous studies have highlighted a detrimental role for extracellular adenosine in cancer, as it dampens T cell–mediated immune responses. Here, we determined that, in contrast to other cancers, CD73 is markedly downregulated in poorly differentiated and advanced-stage endometrial carcinoma compared with levels in normal endometrium and low-grade tumors. In murine models, CD73 deficiency led to a loss of endometrial epithelial barrier function, and pharmacological CD73 inhibition increased in vitro migration and invasion of endometrial carcinoma cells. Given that CD73-generated adenosine is central to regulating tissue protection and physiology in normal tissues, we hypothesized that CD73-generated adenosine in endometrial carcinoma induces an innate reflex to protect epithelial integrity. CD73 associated with cell-cell contacts, filopodia, and membrane zippers, indicative of involvement in cell-cell adhesion and actin polymerization–dependent processes. We determined that CD73-generated adenosine induces cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CDC42–dependent conformational change of the actin-related proteins 2 and 3 (ARP2/3) actin polymerization complex member N-WASP. Cortical F-actin elevation increased membrane E-cadherin, β-catenin, and Na⁺K⁺ ATPase. Together, these findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression. Moreover, our data indicate that the role of CD73 in cancer is more complex than previously […]
Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

Jessica L. Bowser,1 Michael R. Blackburn,2 Gregory L. Shipley,3 Jose G. Molina,2 Kenneth Dunner Jr.,4 and Russell R. Broaddus5

1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2Department of Biochemistry and Molecular Biology and 3Department of Integrative Biology and Pharmacology, The University of Texas Medical School at Houston, Houston, Texas, USA. 4Department of Cancer Biology and 5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Introduction
Ecto-5′-nucleotidase (CD73) is central to the generation of extracellular adenosine. Previous studies have highlighted a detrimental role for extracellular adenosine in cancer, as it dampens T cell–mediated immune responses. Here, we determined that, in contrast to other cancers, CD73 is markedly downregulated in poorly differentiated and advanced-stage endometrial carcinoma compared with levels in normal endometrium and low-grade tumors. In murine models, CD73 deficiency led to a loss of endometrial epithelial barrier function, and pharmacological CD73 inhibition increased in vitro migration and invasion of endometrial carcinoma cells. Given that CD73-generated adenosine is central to regulating tissue protection and physiology in normal tissues, we hypothesized that CD73-generated adenosine in endometrial carcinoma induces an innate reflex to protect epithelial integrity. CD73 associated with cell–cell contacts, filopodia, and membrane zippers, indicative of involvement in cell-cell adhesion and actin polymerization–dependent processes. We determined that CD73-generated adenosine induces cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CDC42-dependent conformational change of the actin-related proteins 2 and 3 (ARP2/3) actin polymerization complex member N-WASP. Cortical F-actin elevation increased membrane E-cadherin, β-catenin, and Na/K+ ATPase. Together, these findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression. Moreover, our data indicate that the role of CD73 in cancer is more complex than previously described.

Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: October 27, 2014; Accepted: November 3, 2015.
complex role of CD73 in cancer, our work highlights the idea that epithelial cells are programmed to maintain cell-cell adhesions. And, like other epithelial cell components such as E-cadherin that must be downregulated for tumor progression to occur, the mediators of this important reflex must also be downregulated.

Results

**CD73 is downregulated in poorly differentiated, invasive, and metastatic endometrial carcinomas.** We measured the expression of CD73 in normal endometrium and endometrial carcinomas of varying histotypes (endometrioid and nonendometrioid), tumor grade, and surgical stage. We detected no significant differences in CD73 mRNA levels between normal endometrium (N-Endo) and grade-1 endometrial endometrioid carcinomas (G1 EECs) (Figure 1A), which are well-differentiated tumors that rarely metastasize. Compared with CD73 mRNA levels in N-Endo, the levels were significantly lower in G3 EECs and nonendometrioid uterine papillary serous carcinomas (UPSCs), both of which are poorly differentiated, high-grade tumors that are associated with deep myometrial invasion and
metastasis. We found that CD73 expression was also lower in the most common epithelial subtype of ovarian cancer — HGSC of the ovary, which microscopically resembles UPSC and has a similarly aggressive clinical course (Figure 1B and ref. 32). We evaluated CD73 expression in relation to type I and type II classifications and surgical stage. Type II carcinomas are more clinically aggressive compared with type I carcinomas. We found that CD73 expression levels were significantly lower in type II tumors (Figure 1C) and in endometrial carcinomas associated with myometrial invasion (International Federation of Gynecology and Obstetrics [FIGO] stages IB and IC) and extraterine disease (FIGO stages II, III, and IV) compared with levels detected in noninvasive tumors (FIGO stage IA; Figure 1D). High CD73 expression levels were associated with prolonged overall survival ($P = 0.015$; hazard ratio, 0.3606; 95% CI, 0.1486–0.8747) (Figure 1E). We also assessed CD73 expression in The Cancer Genome Atlas (TCGA) endometrial cancer data set ($n = 270$ EECs, $n = 53$ UPSCs; ref. 33 and Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI79380DS1). TCGA data are in agreement with our results; CD73 expression levels were significantly higher in endometrioid carcinomas (especially for grades 1 and 2) compared with levels in UPSCs.

The mRNA levels of other genes important for the regulation and activity of extracellular adenosine, including adenosine deaminase (ADA), equilibrative nucleoside transporter 1 (ENT1), the adenosine receptors $A_1$, $A_2$, $A_2$, and $A_3$, and the adenosine receptor effector osteopontin ($SSP1$), were also measured in the same set of endometrial carcinomas. Only CD73 expression was consistently and significantly altered with the different prognostic factors for endometrial cancer (Supplemental Table 1).

We measured CD73-specific activity by reverse-phase HPLC (RP-HPLC) in N-Endo and representative G1 EEC and G3 EEC (Figure 1F) and found that CD73-generated adenosine levels were significantly lower in G3 EEC (Figure 1G). CD73 activity accounted for 82% ± 4% and 79% ± 3% of the adenosine produced in N-Endo and G1 EEC, respectively. CD73-generated adenosine levels were also lower in HGSC of the ovary compared with levels detected in normal ovary (N-Ovary) (Figure 1H). CD73-specific activity was significantly correlated with CD73 mRNA levels in both cancer types ($P = 0.0001$, Pearson’s $r = 0.8896$; Figure 1F; $P = 0.0001$, Pearson’s $r = 0.8916$; Figure 1G).

**CD73 loss occurs in carcinoma cells.** We next sought to localize the loss of CD73 expression in endometrial carcinomas. Cryosections of N-Endo and CD73hi (G1 EEC) and CD73 low (G3 EEC and UPSC) were labeled with anti-human CD73 and the epithelial cell marker pan-cytokeratin. Arrows indicate glandular epithelial cells (N-Endo) or carcinoma cells (G1 EEC and G3 EEC). Asterisks indicate stromal cells and/or connective tissue. (C) High-magnification images of glandular epithelial cells (N-Endo) and carcinoma cells from a G1 EEC gland. CD73 was expressed on apical and basolateral membranes. Scale bars: 50 μm (A and B), 20 μm (C).
levels in carcinoma cells of G3 EEC and UPSC were lower compared with levels detected in G1 EEC and N-Endo glandular epithelial cells (Figure 2, A and B). CD73 was also low in carcinoma cells of metastases involving the peritoneum, omentum, and ovary (peritoneal metastasis #1, Figure 2B; omental and ovarian metastases #2–5, Supplemental Figure 2). Higher-grade endometrial carcinomas showed low expression levels of stromal CD73 that were comparable to those detected in N-Endo and G1 EEC, indicating that, although CD73 loss occurs in the carcinoma cells of tumors, stromal CD73 is not upregulated as a compensatory response. At high magnification, we observed CD73 on apical and basolateral membranes of epithelial cells of N-Endo and G1 EEC endometrial carcinoma cells (Figure 2C).

**CD73 is associated with epithelial differentiation and prevents hypoxia-mediated breakdown of the epithelial barrier.** Data from Figures 1 and 2 suggest that CD73 is related to epithelial differentiation in the endometrium. This finding was also supported in vitro. CD73 mRNA levels and specific activity were significantly lower in moderately and poorly differentiated endometrial carcinoma cell lines compared with those detected in the well-differentiated HEC-1-A and HEC-1-B cells (Supplemental Figure 3). We further assessed this association in Wistar Institute Susan Hayflick (WISH) cells, which spontaneously transition from a mesenchymal-like to an epithelial-like growth pattern (Supplemental Figure 4A) and differentiation state (Supplemental Figure 4B) with increasing confluency. CD73 mRNA levels were significantly increased in WISH cells that had epithelial-like differentiation (100% and 2 Day-Post and 4 Day-Post confluency; Supplemental Figure 4C). CD73 was also localized to cells in closer proximity to each other (more epithelial-like; Supplemental Figure 4D), suggesting that CD73 is important for epithelial integrity.

CD73-generated adenosine protects tissue integrity by inducing endothelial (22–24) and intestinal epithelial (25) barrier function. Therefore, we examined the effect of CD73 deficiency on the epithelial barrier in normal endometrium. Uterine horns of CD73-deficient (Cd73−/−) mice were perfused in vivo with ruthenium red, and loss of barrier function was assessed by electron microscopic examination of ruthenium red paracellular permeability occurring in Cd73−/− mice in normoxia; Cd73−/− mice generally do not show a loss in barrier function until hypoxic (Figure 3B and ref. 24). With whole-animal hypoxia (7% O2, 4 hours), a significant increase in ruthenium red paracellular permeability occurred in Cd73−/− mice compared with C57BL/6 and normoxic Cd73−/− mice, indicating loss of barrier function (Figure 3B). Representative electron photomicrographs of uterine sections from C57BL/6 and Cd73−/− mice exposed to hypoxia (7% O2) for 4 hours (Figure 3A). We found, as expected, that barrier function was comparable between Cd73−/− and C57BL/6 mice in normoxia; Cd73−/− mice generally do not show a loss in barrier function until hypoxic (Figure 3B and ref. 24). With whole-animal hypoxia (7% O2, 4 hours), a significant increase in ruthenium red paracellular permeability occurred in Cd73−/− mice compared with C57BL/6 and normoxic Cd73−/− mice, indicating loss of barrier function (Figure 3B).
Specific proteins often associate with filopodia on the basis of function. For example, E-cadherin localizes with cell-cell filopodia and β1 integrins with focal adhesion filopodia (36, 37). We questioned whether CD73 expression was specific to cell-cell filopodia. Both filopodia of focal adhesions and cell-cell contacts are short-length filopodia. E-cadherin (Supplemental Figure 5, A and B; HEC-1-B cells did not express E-cadherin, data not shown) and CD73 (Figure 5, A and B) localized only with the filopodia of cell-cell contacts in HEC-1-A cells and were both absent from the filopodia of focal adhesions.

In mammalian epithelial cells (38, 39), Caenorhabditis elegans (40, 41), and Drosophila melanogaster (42–44), cell-cell filopodia are central to forming intercellular adhesions. Filopodia from opposing cells interdigitate progressively down the length of the membrane, aligning the two membranes and establishing initial, then mature, intercellular adhesions (45). These structures are known as membrane zippers (39). Both HEC-1-A and HEC-1-B cells showed apparent membrane zippers with ecto-AMPase activity (HEC-1-B cells, Figure 5C; HEC-1-A cells, Supplemental Figure 6). Long- and short-length cell-cell filopodia are shown in Figure 5C; however, high ecto-AMPase activity occurred only with short-length filopodia (approximately ≤3 μM in length; Figure 5C, accompanying...
graph), which are filopodia indicative of intercellular adhesions. Collectively, these associations suggest that CD73-generated adenosine regulates cell-cell adhesions.

**CD73-generated adenosine regulates membrane filamentous actin.** Given that filamentous actin (F-actin) is the primary component of filopodia and membrane zippers are dependent on actin polymerization (39), we hypothesized that CD73-generated adenosine regulates cell-cell adhesions by regulating F-actin. We observed a strong association between CD73 and circumferential cortical F-actin (Figure 5D, HEC-1-A cells, \(P < 0.001, \text{Pearson's} r = 0.7081; \) Supplemental Figure 7A, HEC-1-B cells, \(P < 0.001, \text{Pearson's} r = 0.7198\)). Importantly, we found that cells merely in contact with each other, without sufficient cortical F-actin, were not associated with CD73 (see cells with asterisks in Figure 5D and HEC-1-B cells in Supplemental Figure 7, B–D). Changes in F-actin were assessed by isolating total actin from confluent HEC-1-A cells exposed to hypoxia (1% O\(_2\), 5% CO\(_2\)) for 36 hours and treated with the CD73 inhibitor AoPCP for 50 minutes. Hypoxia was used as a tumor-relevant stressor (46). Inhibition of CD73 resulted in a 43%–54% decrease in total F-actin (Figure 6A). This decrease in F-actin was accompanied by an increase in globular actin (G-actin), which was expected, given the short duration (50 minutes) between treatment time and actin isolation. The G-actin/F-actin ratio (non-normalized data; samples individually assessed for parallel F-actin decrease/G-actin increase) for untreated HEC-1-A cells and HEC-1-A cells treated with 5’-AMP, 5’-AMP plus AoPCP no. 1, or 5’-AMP plus AoPCP no. 2 is shown in Figure 6B. Phalloidin staining showed that F-actin was primarily at the membrane of untreated and 5’-AMP–treated HEC-1-A cells (Figure 6C). AoPCP-treated cells, however, showed a 42% decrease in cortical F-actin (Figure 6, C and D). This was similar to the decrease in F-actin levels observed by isolating total actin, indicating that the regulation of F-actin by CD73-generated adenosine is, in large part, specific to cortical actin.
To examine whether increasing CD73 increases F-actin, we first examined whether CD73 is induced by hypoxia in endometrial carcinoma cells. Hypoxia-inducible factor 1α (HIF-1α) induces CD73 and A2BR expression in models of barrier function (25, 47). Contrary to our expectations, CD73 was not induced in HEC-1-A or HEC-1-B cells, but A2BR was induced (Supplemental Figure 10). Therefore, we treated HEC-1-A cells with increasing concentrations of human recombinant CD73 for 50 minutes. Total actin was isolated from confluent HEC-1-A cells and exposed to hypoxia (1% O2, 5% CO2) for 36 hours. Total F-actin increased by 23% with 100 ng/ml recombinant CD73 (Figure 7A), accompanied by a significant decrease in G-actin. We observed similar F-actin increases of 20% and 16% with 1 ng/ml and 10 ng/ml recombinant CD73 treatment, respectively, but these increases did not reach significance (P = 0.054, 1 ng/ml; P = 0.144, 10 ng/ml). The non-normalized data, expressed as a G-actin/F-actin ratio, are shown in Figure 7B. Phalloidin staining showed a 27% increase in cortical F-actin with 100 ng/ml human recombinant CD73 treatment (Figure 7C, accompanying graph). We observed similar results in HEC-1-A cells treated with 5′-nucleotidase from Crotalus atrox venom (Supplemental Figure 11). Total F-actin increased by 47% after treatment with
0.01 U *Crotalus atrox* 5′-nucleotidase, and phalloidin staining showed a significant increase in F-actin at the membrane (21%; \( P < 0.001 \)). We found that G-actin levels decreased as well. The G-actin/F-actin ratios were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.

To assess whether increasing extracellular adenosine would increase F-actin levels, we treated confluent HEC-1-A cells exposed to hypoxia (1% \( \text{O}_2 \), 5% \( \text{CO}_2 \)) for 36 hours with increasing concentrations of the adenosine deaminase inhibitor 2′-deoxycoformycin (DCF) for 50 minutes. We found that treatment with DCF (10 \( \mu \text{M} \)) increased total F-actin levels by 37% (Figure 7D) and was accompanied by a decrease in G-actin levels. Similar to what we observed with lower concentrations of recombinant CD73, lower concentrations of DCF (100 nM and 1 \( \mu \text{M} \)) resulted in a statistically insignificant 20% decrease in total F-actin levels. The ratios of G-actin/F-actin were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.

To assess whether increasing extracellular adenosine would increase F-actin levels, we treated confluent HEC-1-A cells exposed to hypoxia (1% \( \text{O}_2 \), 5% \( \text{CO}_2 \)) for 36 hours with increasing concentrations of the adenosine deaminase inhibitor 2′-deoxycoformycin (DCF) for 50 minutes. We found that treatment with DCF (10 \( \mu \text{M} \)) increased total F-actin levels by 37% (Figure 7D) and was accompanied by a decrease in G-actin levels. Similar to what we observed with lower concentrations of recombinant CD73, lower concentrations of DCF (100 nM and 1 \( \mu \text{M} \)) resulted in a statistically insignificant 20% decrease in total F-actin levels. The ratios of G-actin/F-actin were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.

To assess whether increasing extracellular adenosine would increase F-actin levels, we treated confluent HEC-1-A cells exposed to hypoxia (1% \( \text{O}_2 \), 5% \( \text{CO}_2 \)) for 36 hours with increasing concentrations of the adenosine deaminase inhibitor 2′-deoxycoformycin (DCF) for 50 minutes. We found that treatment with DCF (10 \( \mu \text{M} \)) increased total F-actin levels by 37% (Figure 7D) and was accompanied by a decrease in G-actin levels. Similar to what we observed with lower concentrations of recombinant CD73, lower concentrations of DCF (100 nM and 1 \( \mu \text{M} \)) resulted in a statistically insignificant 20% decrease in total F-actin levels. The ratios of G-actin/F-actin were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.

To assess whether increasing extracellular adenosine would increase F-actin levels, we treated confluent HEC-1-A cells exposed to hypoxia (1% \( \text{O}_2 \), 5% \( \text{CO}_2 \)) for 36 hours with increasing concentrations of the adenosine deaminase inhibitor 2′-deoxycoformycin (DCF) for 50 minutes. We found that treatment with DCF (10 \( \mu \text{M} \)) increased total F-actin levels by 37% (Figure 7D) and was accompanied by a decrease in G-actin levels. Similar to what we observed with lower concentrations of recombinant CD73, lower concentrations of DCF (100 nM and 1 \( \mu \text{M} \)) resulted in a statistically insignificant 20% decrease in total F-actin levels. The ratios of G-actin/F-actin were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.

To assess whether increasing extracellular adenosine would increase F-actin levels, we treated confluent HEC-1-A cells exposed to hypoxia (1% \( \text{O}_2 \), 5% \( \text{CO}_2 \)) for 36 hours with increasing concentrations of the adenosine deaminase inhibitor 2′-deoxycoformycin (DCF) for 50 minutes. We found that treatment with DCF (10 \( \mu \text{M} \)) increased total F-actin levels by 37% (Figure 7D) and was accompanied by a decrease in G-actin levels. Similar to what we observed with lower concentrations of recombinant CD73, lower concentrations of DCF (100 nM and 1 \( \mu \text{M} \)) resulted in a statistically insignificant 20% decrease in total F-actin levels. The ratios of G-actin/F-actin were as follows: 1.92 ± 0.19 for untreated HEC-1-A cells and 1.70 ± 0.14 for HEC-1-A cells treated with 0.001 U *Crotalus atrox* 5′-nucleotidase, 1.50 ± 0.10 with 0.005 U, and 1.14 ± 0.12 with 0.01 U.
NECA alone, suggesting that A2B R may negatively regulate the induction of F-actin by the A1R. G-actin levels are known to normalize with time (49); accordingly, we found that G-actin levels did not change, given the length of time between treatment and actin isolation (36 hours, Figure 8B). Cell viability was unaltered with NECA or NECA plus adenosine receptor antagonists (Supplemental Figure 13). F-actin, regardless of treatment, was mainly seen at the membrane (Figure 8C). However, in HEC-1-A cells treated with NECA plus DPCPX, we observed a significant (33%) decrease in cortical F-actin (Figure 8, C and D). These data indicate that the regulation of cortical F-actin by CD73-generated adenosine occurs via A1R.

Cell-cell filopodia are shortened by adenosine A1R antagonism. Next, we examined whether the regulation of cortical F-actin by A1R also involves cell-cell filopodia. Confluent HEC-1-A cells

---

**Figure 8. The adenosine A1R antagonist DPCPX decreases cortical F-actin.** (A) Adenosine receptor mRNA expression by real-time qPCR. (B) Representative immunoblot of total actin isolated from confluent HEC-1-A cells treated with DMSO (0.001%), 10 μM NECA, 10 μM NECA plus the A1R antagonist DPCPX (10 μM) or plus the A2B R antagonist MRS1754 (10 μM) in hypoxia (% O2, % CO2) for 36 hours. Graph shows densitometric data from 5 independent experiments. (C) HEC-1-A cells labeled with Alexa Fluor-conjugated phalloidin. (D) F-actin intensity was assessed in 10 or more images (original magnification, ×20). Data represent the mean ± SEM. **P < 0.005 compared with DMSO; *P < 0.05 compared with NECA; and *P < 0.001 compared with NECA plus MRS1754; 1-way ANOVA with Tukey’s post test. Scale bars: 20 μm.

---

**Regulation of cortical F-actin involves the adenosine A1 receptor.** Many of the tissue-protective events attributed to CD73 occur through one or more of four G protein-coupled adenosine receptors: A1R, A2AR, A2BR, and A3R (48). We sought to determine which CD73 regulated F-actin via an adenosine receptor. HEC-1-A and HEC-1-B cells expressed A1R and A2BR, with A1R levels being the highest (Figure 8A). A2AR and A3R were essentially undetectable. We found that A1R was highly expressed by most endometrial carcinoma cell lines. In contrast, breast carcinoma cell lines highly expressed A2BR (Supplemental Figure 12). Total F-actin levels did not significantly change in HEC-1-A cells treated with NECA. However, NECA plus the A1R antagonist DPCPX decreased F-actin levels by 26% (Figure 8B). NECA plus the A2BR antagonist MRS1754 increased total F-actin levels by approximately 19% compared with NECA alone, suggesting that A2BR may negatively regulate the induction of F-actin by the A1R. G-actin levels are known to normalize with time (49); accordingly, we found that G-actin levels did not change, given the length of time between treatment and actin isolation (36 hours, Figure 8B). Cell viability was unaltered with NECA or NECA plus adenosine receptor antagonists (Supplemental Figure 13). F-actin, regardless of treatment, was mainly seen at the membrane (Figure 8C). However, in HEC-1-A cells treated with NECA plus DPCPX, we observed a significant (33%) decrease in cortical F-actin (Figure 8, C and D). These data indicate that the regulation of cortical F-actin by CD73-generated adenosine occurs via A1R.
of adherens junctions (50), it is likely that HEC-1-A cells are engaged with re-forming intercellular adhesions. Additionally, these data show that well-differentiated endometrial carcinoma cells have an intact capacity to generate adenosine and respond to its signaling to induce a physiological reflex, typical of non-neoplastic epithelial cells, to re-form cell-cell adhesions in response to hypoxia.

A1R induces actin polymerization and involves Cdc42 and N-WASP. We next sought to determine whether the regulation of cortical F-actin by A1R is due to A1R-mediated actin polymerization. Confluent HEC-1-A cells were exposed to hypoxia (1% O₂, 5% CO₂) for 36 hours and treated with A1R antagonist DPCPX (1 μM) or plus the A2BR antagonist MRS1754 (1 μM) in hypoxia (1% O₂, 5% CO₂) for 36 hours. HEC-1-A cell membrane borders were enhanced with ruthenium red staining (black deposit) after 36 hours of hypoxia. Filopodia lengths were measured from printed electron photomicrographs, with the print magnification calculated as ×8.5 (print scale bar measurement/actual scale bar measurement). The actual length of individual filopodia was calculated by dividing the print magnification. More than 150 filopodia from 10 or more electron photomicrographs taken from 3 replicates per treatment were measured. Electron photomicrographs show desmosomes bordering areas of interdigitating filopodia (arrows). IF, intermediate filaments. Data represent the mean ± SEM. **P < 0.001; 1-way ANOVA with Tukey’s post test. Scale bars and original magnification: (A) 2 μm, ×5,000 (higher-magnification images in right panels) and (C) 500 nm, ×50,000.

were exposed to hypoxia (1% O₂, 5% CO₂) for 36 hours and then assessed ultrastructurally. Cell-cell filopodia were identified in all of the groups (Figure 9A) but were significantly shorter in HEC-1-A cells treated with the A,R antagonist DPCPX (Figure 9, A and B). We found that filopodia in DMSO-, NECA-, and NECA plus MRS1754–treated cells were completely embedded into the opposing cell and were approximately 1.08–1.13 μm ± 0.02–0.04 μm in length. In primary keratinocytes, filopodia embed into the membrane at a comparable depth of approximately 1.1 μm ± 0.2 μm (39). This depth coincides with the positioning of circumferential cortical F-actin (adhesion belt) and E-cadherin–catenin complexes seen by immunofluorescence, alluding to the formation of intercellular adhesions (39, 45). Notably, we observed desmosomes bordering the sites of the interdigitating filopodia (Figure 9C). Desmosomes flanking interdigitating filopodia are also seen in primary keratinocytes (39). Considering that desmosome assembly is dependent on the preceding assembly of adherens junctions (50), it is likely that HEC-1-A cells are engaged with re-forming intercellular adhesions. Additionally, these data show that well-differentiated endometrial carcinoma cells have an intact capacity to generate adenosine and respond to its signaling to induce a physiological reflex, typical of non-neoplastic epithelial cells, to re-form cell-cell adhesions in response to hypoxia.

A1R induces actin polymerization and involves Cdc42 and N-WASP. We next sought to determine whether the regulation of cortical F-actin by A1R is due to A1R-mediated actin polymerization. Confluent HEC-1-A cells were exposed to hypoxia (1% O₂, 5% CO₂) for 36 hours and treated with the A1R agonist N(6)-cyclopentyladenosine (CPA). Significant total F-actin increases of 30% and 28% were seen after treatment with 1 μM and 10 μM CPA, respectively (Figure 10A), and no alteration in cell viability was observed (Supplemental Figure 14). Phallolidin staining showed that the change in F-actin was primarily at the membrane (Figure 10B).
Cortical F-actin intensity significantly increased with 1 μM CPA (26%) and 10 μM CPA (24%) treatment (Figure 10C).

The Rho GTPase family member CDC42 and neural Wiskott-Aldrich syndrome protein (N-WASP), a ubiquitously expressed CDC42-interacting protein, are important mediators of actin polymerization in mammalian cells (51), and both are implicated in filopodia formation (52–54). N-WASP is normally held in an autoinhibitory conformation. Actin polymerization occurs via binding of CDC42 to N-WASP, releasing its autoinhibition and thereby allowing for the binding of actin-related proteins 2 and 3 (ARP2/3) (Figure 10D and ref. 51). In HEC-1-A cells treated with 10 μM CPA, N-WASP was coimmunoprecipitated by CDC42 (Figure 10E, top left panel), and CDC42 was coimmunoprecipitated by N-WASP (Figure 10E, bottom left panel), indicating that A1R induces actin polymerization involving the ARP2/3 actin polymerization complex.

**Intercellular adhesion proteins increase at the membrane with the A1R agonist CPA.** Given that CPA increased cortical F-actin, we...
considered that an increase in intercellular adhesions would follow. We found that E-cadherin, β-catenin, and Na⁺K⁺ ATPase were increased in membrane fractions of HEC-1-A cells treated with 10 μM CPA (Figure 11A). Cytoplasmic fractions showed decreased β-catenin and Na⁺K⁺ ATPase expression (Figure 11A). We found that total protein expression did not change, indicating that A₁R induces intercellular adhesions involving recycled proteins. Notably, the movement of Na⁺K⁺ ATPase to the membrane is dependent on membrane localization of E-cadherin and coincides with the reorganization of cortical F-actin (55). Immunofluorescence also showed an increase in membrane E-cadherin, β-catenin, and Na⁺K⁺ ATPase and lower cytoplasmic expression with CPA treatment (Figure 11, B–D).

**Loss of CD73-generated adenosine promotes migration and invasion.** We have shown that high-grade and advanced-stage endometrial carcinomas are associated with loss of CD73 and that CD73 is essential for protecting epithelial integrity (inducing the re-formation of cell-cell adhesions). We hypothesized that inhibition of CD73 in well-differentiated endometrial carcinoma cells would promote cellular migration and invasion in...
vitro. We found that CD73 siRNA increased HEC-1-B cell migration and invasion by approximately 60% (Table 1) and HEC-1-A migration by approximately 80% (Table 1). HEC-1-A cells did not invade under 1% O₂, 5% CO₂ hypoxic conditions. Similarly, treatment of cells with the CD73 inhibitor AoPCP increased HEC-1-B cell migration and invasion by approximately 70% (Table 1), indicating that endometrial carcinoma cell migration and invasion is dependent on the loss of CD73-generated adenosine. We observed that AoPCP increased HEC-1-A cell migration by approximately 130% (Table 1). CD73 siRNA efficiency was approximately 90% (Supplemental Figure 16A), and AoPCP efficiencies for HEC-1-A and HEC-1-B cells are shown in Supplemental Figure 16B. We found that NECA reversed the effects of CD73 siRNA and AoPCP treatment (Table 1). Representative images are shown in Supplemental Figure 17.

**Discussion**

In the present study, we explored the effects of loss of CD73 in endometrial carcinoma. We showed that CD73-generated adenosine protects epithelial integrity in normal endometrium, that this physiological reflex is intact in early-stage endometrial carcinomas, and that loss of CD73 is associated with tumor progression. Additionally, we showed that CD73-generated adenosine protects epithelial integrity via adenosine receptor–mediated actin polymerization, which specifically involves A₂R (Figure 12).

CD73 is overexpressed in a number of human tumors, and previous studies have highlighted the detrimental role of extra-cellular adenosine in tumor progression. There are exceptions, including the findings that CD73 is downregulated in prostate (56) and laryngeal (57) carcinomas and with higher tumor grade in colon carcinomas (58), that CD73 overexpression is associated with well-differentiated tumors and better prognosis in ovarian carcinomas, and that CD73 expression is associated with both good and poor prognosis in breast cancer (59, 60). Endometrial carcinomas were recently reported to highly express CD73, but no difference in expression was seen between endometrial carcinomas and the adjacent benign endometrium (61). The tumors from this study were mainly FIGO stage I (n = 24 of 29). Our data showed that early-stage, specifically FIGO IA, tumors have CD73 expression comparable to that of normal, proliferative endometrium. To our knowledge, this is the first study to show a mechanistic basis for why CD73 loss in human cancer promotes tumor progression. By providing evidence for the crucial role of CD73 loss in promoting tumor progression, we hope to pave the way for different perspectives regarding CD73 in cancer.

It has been suggested that epigenetic silencing of CD73 in early-stage disease may abrogate differentiation and promote migration in a subset of melanomas (62). However, it is not clear whether CD73-generated adenosine protects cell-cell adhesions and epithelial integrity in other cancer types, as there are numerous examples of tissue- and cell-specific differences in the expression and function of CD73. In normal breast, CD73 is mostly absent from ductal and acinar epithelial cells, whereas myoepithelial cells express CD73 more frequently (63). High CD73 expression levels are generally found in triple-negative breast cancer (TNBC) cell lines (i.e., MDA-MB-231 and MDA-MB-468; ref. 64) and in TNBC tumors compared with levels detected in other breast cancer cell lines (i.e., MCF-7 and T47D) and tumor subtypes, such as luminal and HER2² tumors (3, 15). RNAi knockdown (9, 12) and CD73 Ab treatment (3) in TNBC breast cancer models decreased tumor growth and metastasis. TNBC and MDA-MB-231 cells both share gene expression signatures similar to those of basal/myoepithelial cells of the breast (65, 66). High expression levels of CD73 have also been related to certain stem cell populations in the mammary gland (67), so it is possible that high CD73 levels in TNBC is a major factor in promoting the aggressive, “stem-like” nature of these tumors. Thus, epithelial CD73 in different tissues may have distinct roles compared with those of endometrial epithelial cells. Accordingly, primary myoepithelial cells from normal human breast tissue exhibit a highly invasive capacity when grown at low density (66). There are regional differences in CD73 expression in epithelial cells of the gastrointestinal tract (41). Within the same tissue region, CD73 expression can also differ. In the ileum, villus absorptive cells do not express CD73, while crypt cells are positive (41). CD73 function can also differ in the same cell type from tissue to tissue. For example, CD73 in vascular endothelium regulates leukocyte trafficking, but does not affect leukocyte movement across lymphatic endothelium (42). In the immune system, naïve T lymphocytes express CD73, but CD73 is absent on effector T cells (68) and is enriched intracellularly in Tregs (69). Functionally, these T cells respond to adenosine via A₂R, but differ in their responses (effector cells are inactivated, while Treg activity increases) (70, 71). Similar heterogeneity is

---

**Table 1. Migration and invasion with CD73 knockdown or with the CD73 inhibitor AoPCP**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HEC-1-B, % Migration ± SEM</th>
<th>HEC-1-B, % Invasion ± SEM</th>
<th>HEC-1-A, % Migration ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parental</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Nontargeting siRNA</td>
<td>89.00 ± 6.10</td>
<td>123.90 ± 8.58</td>
<td>122.10 ± 23.34</td>
</tr>
<tr>
<td>CD73 siRNA</td>
<td>162.10 ± 2.95</td>
<td>182.10 ± 6.67</td>
<td>201.60 ± 9.71</td>
</tr>
<tr>
<td>CD73 siRNA + NECA</td>
<td>125.20 ± 3.88</td>
<td>117.70 ± 11.93</td>
<td>160.40 ± 6.76</td>
</tr>
<tr>
<td>5'-AMP</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td>5'-AMP + AoPCP</td>
<td>173.90 ± 3.59</td>
<td>178.90 ± 29.14</td>
<td>232.10 ± 9.71</td>
</tr>
<tr>
<td>5'-AMP + AoPCP + NECA</td>
<td>141.00 ± 2.97</td>
<td>108.50 ± 7.34</td>
<td>194.80 ± 6.98</td>
</tr>
</tbody>
</table>

*P < 0.001 compared with nontargeting siRNA or 5'-AMP; and P < 0.001 compared with CD73 siRNA or 5'-AMP plus AoPCP. P values were calculated by 1-way ANDVA with Tukey’s post test. Data represent 2 independent experiments performed in triplicate.

---
seen in the expression of adenosine receptors, with different patterns observed for breast (refs. 3, 72 and Supplemental Figure 12) and colon (73, 74) epithelial cells, innate and adaptive immune cells (75), and endothelial cells (23, 76, 77).

Though CD73 loss promotes tumor progression in endometrial carcinoma, our finding that CD73-generated adenosine induces a physiological reflex to protect epithelial integrity is not far removed from the original thought by Ohta and Sitkovsky that extracellular adenosine protects cancerous tissue via its immunosuppressive actions (16). Extracellular adenosine/A2A signaling is a critical axis that limits inflammatory responses, protecting normal tissues from damage (18). Similarly, extracellular adenosine/A2A signaling on immune cells constitutes the basis of immune escape in tumors, protecting cancers by inhibiting the influx of antitumor T cells (16). Many nonimmune-related actions of CD73 promote tumor progression. However, the potent immunosuppressive action of extracellular adenosine is the major factor in CD73-mediated tumor progression (3–8). This is highlighted by studies showing that CD73-deficient mice resist tumor growth and experimental metastasis in many cancer models, largely because of CD8+ T cells (5–7). Immune escape is attributed to CD73 expression in both tumor and nontumor cells (3–8). We observed no change in CD73 expression levels in the stromal cells of endometrial tumors by immunofluorescence. It is certainly possible that nontumor-cell CD73 mediates tumor progression. Tumor resistance in CD73-deficient mice does not correlate with CD73 expression on tumor cells (5). The generation of extracellular adenosine for epithelial integrity could simultaneously induce immunosuppression as well. In tumors with seemingly opposing CD73 actions, deciphering the mechanisms underlying these events in the presence of tumor-host cell interactions will be critical to understanding which adenosine-regulated responses predominate. Interestingly, high densities of CD8+ cells were recently associated with poor prognosis in prostate cancers in which CD73 was expressed at high levels in adjacent normal prostate epithelium (78). The authors suggest that this CD73 expression may provide immune escape by converting surveying CD8+ T cells into immunosuppressive cells (78).

We found in the immunoresponsive TCGA subset of endometrial carcinomas (characterized by higher expression levels of immune response–related genes) that CD73 expression levels were significantly lower compared with those in the hormonal subset (characterized by higher expression levels of hormone receptors and genes induced by estrogen; Supplemental Figure 1C). Genes that characterize the immunoresponsive subset (CD74, CD14, TNFRSF1B, and CEBPD) have been shown to both activate and suppress immune responses (79–84). No differences in inflammatory cell infiltrates were seen in the different endometrial carcinoma subtypes (Supplemental Figure 4.7 in ref. 33), although different lymphocyte populations were not assessed. Future studies are necessary to understand the signif-
icance of lower CD73 expression levels in this cancer subtype. It is reasonable to hypothesize that CD73-mediated cell-cell adhesions may be indirectly immunosuppressive. The role of CD73-mediated cell-cell adhesion in tumors is comparable to that of CD73 in maintaining barrier function in the gut (25). In the gut, breakdown of the intestinal epithelial cell barrier contributes to the development of colitis and inflammatory bowel disease (85). Thus, in both colitis and endometrial cancer, a major determinant of disease severity is loss of epithelial cell CD73 (74, 86, 87). Damage to the epithelial barrier results in the production of inflammatory mediators by immune cells and epithelial cells (88). Inducing epithelial integrity in the early stages of disease may be a way to protect the developing/growing tumor from its own induction of proinflammatory and antitumor immune actions triggered by damage to the epithelial barrier. CD73-induced cell-cell adhesions may therefore be immunosuppressive simply by acting as a physiological barrier. This possibility or the importance of CD73 expression on nontumor cells in endometrial carcinoma cannot be determined on the basis of our study. The relative contribution of tumor versus stromal and immune cell CD73 and the interaction of cell types in the tumor microenvironment are likely different for different tumor types.

Increased extracellular adenosine in tumors (16, 26) is linked to hypoxia (89). CD73 and A2BR upregulation by HIF-1α promotes barrier function (25, 47), yet CD73 expression was not induced by hypoxia in HEC-1-A or HEC-1-B cells, which suggests an escape mechanism of endometrial carcinoma cells to de-link hypoxia from CD73 upregulation. Notably, the full-length promoter of CD73 contains an area that represses CD73 expression in hypoxia (25). We found that A2BR expression was not uncoupled from hypoxia upregulation. We thus hypothesize that A2BR may counterbalance A1R-mediated actin polymerization. Endometrial carcinomas appear to avoid extracellular adenosine overall, as alkaline phosphatase, another source of extracellular adenosine, is downregulated in poorly differentiated and advanced-stage endometrial carcinomas (90, 91). ENTh, a bidirectional transporter mediating adenosine efflux or intracellular uptake according to the direction of the concentration gradient (92), was also downregulated in advanced-stage endometrial tumors (P < 0.02, Supplemental Table 1), and its expression was positively correlated with that of CD73 (P < 0.0001, Pearson’s r = 0.7010). With CD73 loss, the concomitant loss of ENTh1 would be expected to prevent the movement of higher concentrations of intracellular adenosine to the extracellular space. Decreased adenosine uptake due to ENTh1 downregulation via HIF-1α induces vascular barrier protection (93). Similarly, in tumor types that maintain expression of CD73, ENTh1 downregulation may help protect epithelial integrity by allowing increased extracellular adenosine (93).

A2BR has been the primary adenosine receptor shown to protect endothelial and intestinal epithelial integrity and promote barrier function (22, 23, 94–96). A2BR-deficient mice failed to show a significant difference in epithelial barrier function in normal endometrium (Supplemental Figure 18). A1R is the primary adenosine receptor mediating barrier function in vasa vasorum endothelial cells (VVEC) (77). Similar to endometrial carcinoma cells, VVECs express A1R at higher levels than do other adenosine receptors (77). In VVECs, A1R-mediated barrier function involves actin cytoskeletal rearrangement (77). We showed that A1R induces cortical actin polymerization and extension of cell-cell filopodia for cell-cell adhesions. Actin polymerization is a relatively fast biological action, and the regulation of actin polymerization by extracellular adenosine is consistent with the quick actions needed to re-form cell-cell adhesions and re-seal the barrier. These findings are supported by results from other studies (77, 97, 98). It is likely that CD73/adenosine receptor-mediated actin polymerization is also important in re-forming intercellular adhesions in endothelial cells, as filopodia-like protrusions connected by VE-cadherin–rich junctions have been reported in human umbilical vein endothelial cells (99).

Actin polymerization in cells is balanced by actions (induction of kinases, phosphatases, and actin depolymerization factors) that are induced shortly afterward to keep the actin polymerization response self-limiting (100). We found that treatment with NECA did not significantly affect F-actin, but NECA plus MR31754 increased F-actin, suggesting that A2BR may counterbalance the actions of A1R. This regulation may involve A2BR-mediated activity of vasodilator-stimulated phosphoprotein (VASP). For example, A2BR increases cAMP (101), whereas cAMP interaction of mediating cell-cell adhesions and re-sealing the barrier. These findings are supported by results from other studies (77, 97, 98). It is likely that CD73/adenosine receptor-mediated actin polymerization is also important in re-forming intercellular adhesions in endothelial cells, as filopodia-like protrusions connected by VE-cadherin–rich junctions have been reported in human umbilical vein endothelial cells (99).

In summary, loss of CD73 in endometrial carcinoma is crucial to tumor progression, as it negates the physiological reflex of extracellular adenosine to protect epithelial integrity. Our finding that loss of CD73 promotes tumor progression is counter to the current understanding of CD73 in cancer, but consistent with reports on other types of cancer. This study highlights the complex biology of CD73 and extracellular adenosine in human tumors. Understanding the multiple facets of CD73 in cancer will be important to the future clinical success of CD73-targeted therapeutics.

Methods

See the Supplemental Methods for details on A2BR−/− mice; H&E, immunofluorescence, phalloidin, and annexin V-FITC propidium iodide staining; ecto-AMPase activity; transmission electron microscopy; immunoblotting; siRNA transection; and cell migration and invasion.
Human tissues. EECs, proliferative-phase endometrium, ovarian HGSCs, and N-Ovaries were obtained from the Department of Pathology of the MD Anderson Cancer Center as residual tissues from hysterectomies. For surgical staging details, see Supplemental Table 2.

Mice. Cd73–/– mice (24) were provided by Linda Thompson (Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA) and were maintained on a C57BL/6 background (Harlan Laboratories). Mice were maintained in a 12-hour light/12-hour dark cycle, and female mice estrous cycles were synchronized beginning at 8 weeks of age.

Cell lines. HEC-1-A and HEC-1-B cells (American Type Culture Collection [ATCC]) were maintained according to ATCC recommendations and authenticated by short tandem repeat DNA profiling. Details on all other cell lines used are provided in the Supplemental Methods.

Reagents and Abs. All reagents were purchased from Sigma-Aldrich, unless otherwise indicated. DCF and MRS1754 were from Tocris Biosciences. Human recombinant CD73 was from R & D Systems. S′-Nucleotidase from Crotalus atrox venom was purchased from Sigma-Aldrich (catalog N8661). The complete list of Abs used is provided in Supplemental Table 3.

Plasmids. pRKS5-Myc-CDC42 was a gift of Gary Bokoch (Addgene plasmid 12972). WASL Myc-DDK-tagged Wiskott-Aldrich syndrome-like (WASL, alternatively called N-WASP) was purchased from OriGene (catalog RC207967). Plasmids were propagated in E. coli DH5α and purified on QIAGEN-tip 100 columns (QIAGEN).

RNA extraction and real-time quantitative PCR. RNA was isolated from frozen tissues using TRIzol Reagent (Invitrogen), followed by purification with RNeasy columns (QIAGEN). RNA was isolated from cell lines using Quick-RNA MiniPrep columns (Zymo Research). Details on real-time quantitative PCR (qPCR), assay development, and data analysis are provided in the Supplemental Methods. For the list of primers used and probe sequences, see Supplemental Table 3.

Ruthenium red uterine perfusions. Ten- to fourteen-week-old mice in proestrus were individually placed in a modular incubator chamber (Billups-Rothenberg) and exposed to room air or hypoxia (7% O2) for 4 hours. The proestrus period was selected because of its higher CD73 expression levels in luminal and glandular uterine epithelial cells (109). Additionally, membrane localization of tight-junction proteins increases in rodent uterine epithelial cells during proestrus (110). Following exposure to room air or hypoxia, mice were anesthetized with 0.2 ml/10 g tribromoethanol, and a peritoneal incision was made. Uterine horns were perfusion fixed with 0.2 ml 0.2% ruthenium red and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer and then filled with 0.1 ml 0.2% ruthenium red and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer following closure of the endocervical canal with a surgical thread knot. Anesthetized mice were returned to the chambers for 10 minutes. After removal of the surgical thread, the uterine horns were reperfused, in order, with 0.7 ml 0.2% ruthenium red and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer and 0.2 ml 0.2% ruthenium red in 2% osmium tetroxide in 0.1 M sodium cacodylate buffer. In additional studies, Cd73–/– mice were injected i.p. with NECA 0.1 mg/kg or DMSO prior to being exposed to hypoxia for 4 hours. Dosing and administration of NECA to Cd73–/– mice was similar to that described previously (24).

Isolation of total actin. Total actin was isolated using a G-actin/F-actin In Vivo Assay Biochem Kit (Cytoskeleton). Ultracentrifugation was performed using a Beckman Coulter Optima Max-XP Ultracentrifuge with a Beckman Coulter TLS-55 rotor.

Co-IP. HEC-1-A cells were transfected with pRKS5-Myc-CDC42 or pcMV6-Myc-NWASP (2 μg) in serum-free Opti-MEM (Invitrogen) using Lipofectamine 2000 (Invitrogen). HEC-1-A cells were treated with 10 μM CPA or DMSO in hypoxia (1% O2, 5%) for 36 hours, 24 hours after transfection. Co-IP was performed using a Pierce c-Myc-Tag Magnetic IP/Co-IP Kit (Thermo Scientific). Protein (1 mg) was incubated overnight at 4°C with 25 μl anti-Myc magnetic beads. The resulting immune-bound complexes were eluted in 2X reducing sample buffer and assessed by SDS-PAGE using a 4%-12% gradient polyacrylamide gel (BioRad) and immunoblotting methods.

Cellular fractionation. Cellular fractions were isolated using a Pierce Subcellular Protein Fractionation Kit (Thermo Scientific). Fractions were concentrated using Amicon Ultra Centrifugal Filters (EMD Millipore).

Statistics. P values were calculated using an unpaired t test, 1-way ANOVA with Tukey’s post test, 2-way ANOVA with Bonferroni’s post test, or as otherwise indicated (GraphPad Prism 6; GraphPad Software). Human tissue data were analyzed using a Mann-Whitney U test or Kruskal-Wallis 1-way ANOVA with Dunn’s post test. A P value of less than 0.05 was considered significant. Survival data were collected by review of electronic medical records, and overall survival rates were stratified in a Kaplan-Meier plot according to CD73 mRNA levels.

Study approval. Use of human tissues was approved by the IRB of the University of Texas MD Anderson Cancer Center (LAB01-718). Animal studies were approved by the IACUC of the University of Texas Medical School at Houston.

Author contributions JLB and RRB developed the study concept and design. JLB performed experiments and analyzed the data, and JLB, MRB, and RRB interpreted the data. GLS performed the real-time qPCR studies. JGM bred and genotyped the mice. KD provided expertise on transmission electron microscopy. JLB and RRB wrote the manuscript.

Acknowledgments We thank Linda Thompson for providing the Cd73–/– mice; Steven Curly, Andrew Gladden, and Samuel Mok for providing equipment; Carolyn Hall for helpful discussions; and Jiping Feng for technical assistance. Yuexin Liu provided the CD73 expression data from TCGA endometrial cancer project. This work was supported by NIH grant P50CA098258 (Uterine Cancer SPORE, to R.R. Broaddus); NIH grant TLR024147 from the National Center for Research Resources (to J.L. Bowser); the Interdisciplinary Translational Education and Research Training Program (to J.L. Bowser) in the Department of Translational Molecular Pathology; and the University of Texas MD Anderson Cancer Center NIH Cancer Center Support Grant P30CA016672.

Address correspondence to: Russell R. Broaddus, Department of Pathology, Box 83, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA. Phone: 713.745.2794; E-mail: rbroaddus@mdanderson.org.


5. Chen L, Zhang JQ, Huang XY. cAMP inhibits cell migration by interfering with Rac-induced